Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print July 18, 2007, doi:10.1212/01.wnl.0000268489.60809.c4)
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
01.wnl.0000268489.60809.c4v1
69/12/1254    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yanagisawa, A.
Right arrow Articles by Guicheney, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yanagisawa, A.
Right arrow Articles by Guicheney, P.
Related Collections
Right arrow All Neuromuscular Disease
Right arrow Muscle disease
Right arrow Mental retardation
Right arrow All Genetics
NEUROLOGY 2007;69:1254-1260
© 2007 American Academy of Neurology

New POMT2 mutations causing congenital muscular dystrophy

Identification of a founder mutation

A. Yanagisawa, MD, C. Bouchet, PhD, P.Y.K. Van den Bergh, MD, J. -M. Cuisset, MD, L. Viollet, MD, PhD, F. Leturcq, PhD, N. B. Romero, MD, PhD, S. Quijano-Roy, MD, PhD, M. Fardeau, MD, N. Seta, PhD and P. Guicheney, PhD

From INSERM (A.Y., N.B.R., S.Q.-R., M.F., P.G.), U582, Institut de Myologie, Groupe Hospitalier Pitié-Salpêtrière, Paris; Université Pierre et Marie Curie-Paris 6 (A.Y., N.B.R., S.Q.-R., M.F., P.G.), UMR S 582, IFR 14; AP-HP (C.B., N.S.), Hôpital Bichat-Claude Bernard, Biochimie Métabolique, Paris, France; Service de Neurologie (P.Y.K.V.d.B.), Centre de Référence Neuromusculaire, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Maladies Neuromusculaires de l'Enfant (J.-M.C.), Hôpital Roger Salengro, Lille; INSERM (L.V.), U781, Hôpital Necker-Enfants Malades, Paris; AP-HP (F.L.), Hôpital Cochin, Biochimie et Génétique Moléculaire, Paris; AP-HP (N.B.R., P.G.), Hôpital Pitié-Salpêtrière, Paris; and AP-HP (S.Q.-R.), Hôpital Raymond Poincaré, Pédiatrie, Garches, France.

Address correspondence and reprint requests to Dr. Pascale Guicheney, INSERM U582, Institut de Myologie, Groupe Hospitalier Pitié-Salpêtrière, 47 Bd. de l'Hôpital, 75651 Paris, France p.guicheney{at}myologie.chups.jussieu.fr

Background: Dystroglycanopathies are a group of congenital muscular dystrophies (CMDs) with autosomal recessive inheritance, often associated with CNS and ocular involvement. They are characterized by the abnormal glycosylation of alpha-dystroglycan, and caused by mutations in at least six genes encoding enzymes: FKTN, POMGNT1, POMT1, POMT2, FKRP, and LARGE. POMT2 mutations have recently been identified in Walker-Warburg syndrome and in a milder muscle-eye-brain disease-like form.

Methods: We studied mentally retarded patients with CMD, analyzed POMT2 by sequencing the coding regions, and also performed a haplotype analysis in all patients and their family members carrying the new POMT2 mutation.

Results: We report three novel POMT2 mutations. One of these, p.Tyr666Cys, was homozygous in two unrelated patients and in a compound heterozygous state in others. All patients showed severe diffuse muscle weakness, microcephaly, severe mental retardation, and marked lordoscoliosis with hyperextended head. Elevated CK levels, cerebral cortical atrophy, and cerebellar vermis hypoplasia were constant findings. Mild cardiac abnormalities, focal white matter abnormalities, or partial corpus callosum hypoplasia were detected in single cases. Eye involvement was absent or mild. By genotype analysis, we defined a distinct 170kb haplotype encompassing POMT2 and shared by all the subjects harboring the mutation p.Tyr666Cys.

Conclusions: Our results broaden the clinical spectrum associated with POMT2 mutations, which should be considered in patients with CMD associated with microcephaly, and severe mental retardation with or without ocular involvement.

Supplemental data at www.neurology.org

e-Pub ahead of print on July 18, 2007, at www.neurology.org.

Supported by the Institut National de la Santé et de la Recherche Médicale (INSERM), the Association Française contre les Myopathies (AFM), and the GIS Maladies Rares (Network on Congenital Muscular Dystrophy).

Disclosure: The authors report no conflicts of interest.

Received December 7, 2006. Accepted in final form April 4, 2007.




This article has been cited by other articles:


Home page
 GlycobiologyHome page
M. Lommel and S. Strahl
Protein O-mannosylation: Conserved from bacteria to humans
Glycobiology, August 1, 2009; 19(8): 816 - 828.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
E. Mercuri, S. Messina, C. Bruno, M. Mora, E. Pegoraro, G. P. Comi, A. D'Amico, C. Aiello, R. Biancheri, A. Berardinelli, et al.
Congenital muscular dystrophies with defective glycosylation of dystroglycan: A population study
Neurology, May 26, 2009; 72(21): 1802 - 1809.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
M. R. Ackroyd, L. Skordis, M. Kaluarachchi, J. Godwin, S. Prior, M. Fidanboylu, R. J. Piercy, F. Muntoni, and S. C. Brown
Reduced expression of fukutin related protein in mice results in a model for fukutin related protein associated muscular dystrophies
Brain, February 1, 2009; 132(2): 439 - 451.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by AAN Enterprises, Inc.